Dr. Carlo-Stella on Updated Results on RG6234 Activity in R/R Multiple MyelomaDecember 23rd 2022
Carmelo Carlo-Stella, MD, PhD, discusses updated results from a phase 1 dose-escalation study of subcutaneous and intravenous RG6234 in relapsed/refractory multiple myeloma.
Tisagenlecleucel Shows Promise in Relapsed/Refractory Aggressive B-Cell NHL and Comorbidities in Real-World Setting
Tisagenlecleucel elicited durable efficacy and a favorable long-term safety profile in the real-world setting of patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
BGB-11417 Alone or in Combination with Zanubrutinib Shows Early Efficacy in CLL/SLLDecember 13th 2022
BGB-11417, when given alone or in combination with zanubrutinib, elicited encouraging responses and minimal residual disease negativity rates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to preliminary data from a phase 1 trial.
HD-ASCT Demonstrates Improved PFS Vs Non-Myeloablative Chemoimmunotherapy in Primary CNS LymphomaDecember 13th 2022
Consolidation therapy with high-dose chemotherapy and autologous stem cell transplantation improved progression-free survival vs non-myeloablative chemoimmunotherapy in patients with primary central nervous system lymphoma.
BCMA/CD19 Dual-targeting CAR T-cell Therapy Shows 100% MRD Negativity Rate in Newly Diagnosed Multiple MyelomaDecember 13th 2022
Among patients with newly diagnosed high-risk multiple myeloma, treatment with BCMA/CD19 dual-targeting FasTCAR-T Cells resulted in an overall response rate of 100%, with all treated patients evaluable for minimal residual disease showing minimal residual disease negativity to 12 months.
Dr Peffault de Latour on the Benefit of Iptacopan Vs SOC in PNH and Residual AnemiaDecember 13th 2022
Regis Peffault de Latour, MD, PhD, discusses the benefit observed with iptacopan vs standard-of-care eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria and residual anemia during the phase 3 APPLY-PNH trial.
GVHD Prophylactic Regimen Improves 1-Year GRFS Vs Standard in Patients With Hematologic Malignancies Post-HCTDecember 13th 2022
Administration of cyclophosphamide, tacrolimus, and mycophenolate mofetil improved 1-year GVHD relapse-free survival compared with tacrolimus plus methotrexate in patients with hematologic malignancies undergoing reduced intensity conditioning allogeneic hematopoietic cell transplantation.
Cilta-Cel Shows Efficacy and Tolerability in Multiple Myeloma, Potentially Filling Unmet Need in Early-Line TherapyDecember 13th 2022
The CAR-T cell therapy ciltacabtagene autoleucel has expanded options for adult patients with relapsed/refractory multiple myeloma after 4 or more lines of prior therapy in the United States, and has continued to display promising efficacy in patients with multiple myeloma following early relapse.
Olverembatinib Elicits Efficacy in US Patients With Ponatinib-Resistant, T315I-Mutant CML, and Ph-Positive ALL
Olverembatinib elicited encouraging responses and tolerability in US patients with ponatinib-resistant chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, and in patients with CML whose tumors have a T315I mutation.
Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLLDecember 13th 2022
Treatment with zanubrutinib (Brukinsa) reduced the risk of progression or death by 35% compared with ibrutinib (Imbruvica) for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Blinatumomab/Consolidation Chemo Combo Improves OS in MRD-Negative B-cell ALL
Blinatumomab followed by consolidation chemotherapy led to a 58% reduction in the risk of death compared with standard consolidation chemotherapy alone in adult patients with newly diagnosed minimal residual disease–negative B-cell acute lymphoblastic leukemia.
Amid Withdrawal News, Final DREAMM-2 Analysis Confirms Durability of Belantamab Mafotodin Monotherapy in Relapsed/Refractory Multiple MyelomaDecember 12th 2022
Single-agent belantamab mafodotin continued to produce rapid, deep, and durable responses in patients with relapsed/refractory multiple myeloma.
Zanubrutinib Demonstrates Efficacy and Safety in Acalabrutinib-Intolerant Patients with B-Cell MalignanciesDecember 12th 2022
Updated results from the ongoing phase 2 BGB-3111-215 trial showed that zanubrutinib provided clinically meaningful benefit to a large majority of efficacy-evaluable patients with B-cell malignancies who were intolerant to acalabrutinib.
Momelotinib Responses Upheld Through 48 Weeks in Patients With Anemic Myelofibrosis
Momelotinib elicited durable symptom, transfusion independence, and splenic responses through 48 weeks of treatment in patients with myelofibrosis who have anemia and previously received a JAK inhibitor.
Belantamab Mafodotin Plus Pomalidomide/Dexamethasone Prolongs PFS, Compared With Historical Control in Relapsed/Refractory Multiple MyelomaDecember 12th 2022
The combination of belantamab mafodotin, pomalidomide, and dexamethasone elicited encouraging responses and survival benefits in patients with triple class–exposed or refractory multiple myeloma.
Mosunetuzumab Elicits Long-Term Responses in Relapsed/Refractory Follicular LymphomaDecember 12th 2022
Mosunetuzumab demonstrated durable responses and a low rate of adverse events linked with treatment discontinuation in patients with relapsed/refractory follicular lymphoma, according to an updated analysis of the pivotal phase 2 GO29781 study.
Dr Abramson on the Efficacy of Second-line Liso-cel Vs SOC in Relapsed/Refractory LBCLDecember 12th 2022
Jeremy Abramson, MD, discusses the efficacy data of second-line lisocabtagene maraleucel vs standard-of-care salvage chemotherapy followed by autologous stem cell transplant from the phase 3 TRANSFORM trial done in patients with relapsed/refractory large B-cell lymphoma.
Low-Dose Lenalidomide Reduces Risk of Transfusion Dependency, Provides Clonal Response and Safety Benefits in MDSDecember 12th 2022
Low doses of lenalidomide prolonged time to and decreased the risk of transfusion dependency and induced quality clonal responses with no increases in progression rate or clonal evolution in patients with low-risk myelodysplastic syndrome.
Liso-Cel Second-Line Superiority to Standard of Care Confirmed in LBCLDecember 12th 2022
Second-line treatment with lisocabtagene maraleucel (liso-cel; Breyanzi) reduced the risk of an event occurring by 64.4% compared with standard-of-care chemoimmunotherapy induction and autologous stem cell transplantation for patients with high-risk relapsed/refractory large B-cell lymphoma.
Dr Chari on the MonumenTAL-1 Trial Examining Talquetamab in Multiple MyelomaDecember 12th 2022
Ajay Chari, MD, discusses findings from the phase 1/2 MonumenTAL-1 trial investigating talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma.
Real-World Data Consistent With Patient-Reported Outcomes Regarding Axi-Cel Administration in Relapsed/Refractory LBCLDecember 11th 2022
Patients receiving axicabtagene ciloleucel reported a temporary reduction in quality of life, followed by statistically significant improvements in overall QOL and symptoms within the first year of treatment for relapsed/refractory large B-cell lymphoma.
Ibrutinib Induction/Maintenance Is Highly Effective for MCLDecember 11th 2022
The addition of ibrutinib to standard chemoimmunotherapy induction followed by autologous stem cell transplantation (ASCT) and 2 years of maintenance ibrutinib significantly improved outcomes vs standard chemoimmunotherapy induction and ASCT alone for younger patients with mantle cell lymphoma.